Literature DB >> 23629438

Vascular disease: vorapaxar prevents progression of peripheral artery disease.

William R Hiatt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23629438     DOI： 10.1038/nrcardio.2013.66

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  9 in total

Review 1.  Antiplatelet agents for intermittent claudication.

Authors:  Peng F Wong; Lee Yee Chong; Dimitris P Mikhailidis; Peter Robless; Gerard Stansby
Journal:  Cochrane Database Syst Rev       Date:  2011-11-09

2.  Mortality over a period of 10 years in patients with peripheral arterial disease.

Authors:  M H Criqui; R D Langer; A Fronek; H S Feigelson; M R Klauber; T J McCann; D Browner
Journal:  N Engl J Med       Date:  1992-02-06       Impact factor: 91.245

3.  Vorapaxar in the secondary prevention of atherothrombotic events.

Authors:  David A Morrow; Eugene Braunwald; Marc P Bonaca; Sebastian F Ameriso; Anthony J Dalby; Mary Polly Fish; Keith A A Fox; Leslie J Lipka; Xuan Liu; José Carlos Nicolau; A J Oude Ophuis; Ernesto Paolasso; Benjamin M Scirica; Jindrich Spinar; Pierre Theroux; Stephen D Wiviott; John Strony; Sabina A Murphy
Journal:  N Engl J Med       Date:  2012-03-24       Impact factor: 91.245

Review 4.  Collaborative overview of randomised trials of antiplatelet therapy--II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-15

5.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.

Authors: 
Journal:  BMJ       Date:  2002-01-12

6.  Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.

Authors:  Jeffrey S Berger; Mori J Krantz; John M Kittelson; William R Hiatt
Journal:  JAMA       Date:  2009-05-13       Impact factor: 56.272

7.  Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50.

Authors:  Marc P Bonaca; Benjamin M Scirica; Mark A Creager; Jeffrey Olin; Henri Bounameaux; Mikael Dellborg; Jessica M Lamp; Sabina A Murphy; Eugene Braunwald; David A Morrow
Journal:  Circulation       Date:  2013-03-15       Impact factor: 29.690

8.  2011 ACCF/AHA Focused Update of the Guideline for the Management of patients with peripheral artery disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors: 
Journal:  Circulation       Date:  2011-09-29       Impact factor: 29.690

9.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Authors:  Colin Baigent; Lisa Blackwell; Rory Collins; Jonathan Emberson; Jon Godwin; Richard Peto; Julie Buring; Charles Hennekens; Patricia Kearney; Tom Meade; Carlo Patrono; Maria Carla Roncaglioni; Alberto Zanchetti
Journal:  Lancet       Date:  2009-05-30       Impact factor: 79.321
  9 in total
  1 in total

Review 1.  Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease.

Authors:  Rebecca J Gryka; Leo F Buckley; Sarah M Anderson
Journal:  Drugs R D       Date:  2017-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.